US FDA clears Abbott's continuous glucose monitors for over-the-counter use-February 2024-www.financetom.com

US FDA clears Abbott's continuous glucose monitors for over-the-counter use

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA clears Abbott's continuous glucose monitors for over-the-counter use

Jun 10, 2024 5:21 AM

June 10 (Reuters) - Abbott said on Monday that

the U.S. Food and Drug Administration has cleared its two

continuous glucose monitoring systems for over-the-counter use.

Previous page： Stellantis Allocates $406 Million for Michigan Facilities to Boost EV Production Next page： iRhythm Technologies Secures Japanese Approval for EGC Monitoring Device

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Stellantis Allocates $406 Million for Michigan Facilities to Boost EV Production

Sep 11, 2024

09:01 AM EDT, 09/11/2024 (MT Newswires) -- Stellantis ( STLA ) said Wednesday it plans to invest over $406 million in three of its facilities in Michigan to boost their EV production capacities. The Sterling Heights Assembly Plant will get an investment of $235.5 million as it is expected to produce Stellantis' ( STLA ) first US plant to build...

iRhythm Technologies Secures Japanese Approval for EGC Monitoring Device

Sep 11, 2024

08:45 AM EDT, 09/11/2024 (MT Newswires) -- iRhythm Technologies ( IRTC ) said Wednesday that its 14-day ECG monitoring system, Zio, received regulatory approval from Japan's pharmaceutical and medical device agency. With regulatory approval, the company said it intends to work with the Japanese Ministry of Health, Labour, and Welfare to reach a reimbursement decision for the Zio ECG monitoring...

Actuate Therapeutics Says Elraglusib Granted FDA Orphan Drug Designation; Shares Rise

Sep 11, 2024

08:55 AM EDT, 09/11/2024 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Wednesday that the US Food and Drug Administration has granted orphan drug designation to elraglusib to treat soft tissue sarcoma. The designation is intended to support companies developing medicines for rare disorders that affect fewer than 200,000 people in the US. Shares of the biopharmaceutical company were...

Voya Financial to Acquire OneAmerica's Retirement Plan Business

Sep 11, 2024

08:56 AM EDT, 09/11/2024 (MT Newswires) -- Voya Financial ( VOYA ) said Wednesday it has agreed to acquire OneAmerica Financial's retirement plan business for an upfront purchase price of $50 million. The transaction includes a deferred consideration of up to $160 million, payable in Q2 2026, contingent on plan persistency and transition incentives, the company said. The deal is...